Achilles Therapeutics plc (ACHL )

Currency in USD Disclaimer
$1.36 +$0.25 (22.52%)
Closed 02/04/2025
$1.35
$1.41
$0.63
$1.76

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol ACHL
  • Company Achilles Therapeutics plc
  • Price $1.36
  • Changes Percentage 22.52
  • Change 0.25
  • Day Low $1.35
  • Day High $1.41
  • Year High $1.76
  • Year Low $0.63
  • Market Cap $55,896,054
  • Price Avg 50 EMA (D) $1.09
  • Price Avg 200 EMA (D) $0.93
  • Exchange NASDAQ
  • Volume 9,706,720
  • Average Volume 177,620
  • Open $1.37
  • Previous Close $1.11
  • EPS -1.66
  • PE -0.82
  • Earnings Announcement 2025-04-02 12:30:00
  • Shares Outstanding $41,100,040

Company brief: ACHILLES THERAPEUTICS PLC (ACHL )

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.

ACHL Corporation News

Income Statement